Vantage Biosciences Doses First Patient in Phase II Clinical Study of Oral VX-01 for Non-Proliferative Diabetic Retinopathy

Vantage Biosciences announced that the first patient has been successfully dosed in its Phase II clinical study evaluating VX-01, an oral therapy for the treatment of non-proliferative diabetic retinopathy.